NewEdge Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

NewEdge Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$10.7K	–	4120
2024 Q4	$10.7K	Buy	+10,000	New	+$32.2K	﹤0.01%	3020

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

NewEdge Advisors's XERS Position: Q1 2025 in Review

NewEdge Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 10,000 shares — an estimated $10.7K sold.

NewEdge Advisors first reported a position in XERS in Q4 2024 and held it in 1 quarter. The position peaked at $10.7K in Q4 2024. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

NewEdge Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
NewEdge Advisors sold 10,000 Xeris Biopharma Holdings shares in Q1 2025, an estimated $10.7K.
NewEdge Advisors first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 1 quarter.
NewEdge Advisors's Xeris Biopharma Holdings position peaked at $10.7K in Q4 2024.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.